AT64748B - Process for obtaining the therapeutically active substance contained in the pituitary in crystallized form. - Google Patents
Process for obtaining the therapeutically active substance contained in the pituitary in crystallized form.Info
- Publication number
- AT64748B AT64748B AT64748DA AT64748B AT 64748 B AT64748 B AT 64748B AT 64748D A AT64748D A AT 64748DA AT 64748 B AT64748 B AT 64748B
- Authority
- AT
- Austria
- Prior art keywords
- pituitary
- active substance
- obtaining
- substance contained
- therapeutically active
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims description 6
- 230000001817 pituitary effect Effects 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims description 4
- 206010062767 Hypophysitis Diseases 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 210000003635 pituitary gland Anatomy 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229910052601 baryte Inorganic materials 0.000 description 2
- 239000010428 baryte Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- SWJBITNFDYHWBU-UHFFFAOYSA-N [I].[I] Chemical compound [I].[I] SWJBITNFDYHWBU-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Gewinnung der in den Hypophysen enthaltenen therapeutisch wirksamen
Substanz in kristalll8ierter Form.
Es ist bekannt, dass Extrakte aus dem wirksamen Teil der Hypophyse (Hypophysis cerebri), dem sogenannten Infundibularanteil, die Fähigkeit besitzen, durch Kontraktion der peripheren Gefässmuskulatur Blutdruckänderung hervorzurufen und den Uterus durch Steigerung der Erregbarkeit der sympatischen Uterusnerven zu Kontraktionen anzuregen. Namentlich wegen letzterer Eigenschaft, wodurch die Geburtswehen sehr verstärkt werden. haben diese Hypophysenextrakte eine grosse therapeutische Bedeutung erlangt.
Bislang kommen nur verdünnte Auszüge aus dem lufundibularanteil der Hypophyse unter dem Namen Pituitrin, Pitglandol usw. n den Handel. die in der Weise eingestellt sind, dass 1 cm3 einer solchen Lösung 0#2 g Infu7ndibularanteil entspricht. Da aber der Gehalt an wirksamer Substanz in der Hypophyse nicht immer der gleiche ist und eine einfache Wertbestimmung der Hypoplivsenextrakte nicht bekannt ist, schwankt naturgemäss die Wirkung dieser Extrakte in weiten Grenzen, was sich bei der therapeutischen Anwendung dieser Präparate störend bemerkbar machte.
Es ist nun gelungen. die wirksame Substanz der Hypophyse in Form eines gui kristallisierten und in Wasser leicht löslichen Salzes zu isoileren. Da dieses Salz chemisch rein ist, können davon Lösungen von stets gleichem Wirkungswert hergestellt werden.
Das Verfahren besteht darin, dass man die vom Eiweiss vollständig befreiten Extrakte aus dem wirksamen Teil der Hypophyse mit den gebrauchhchen Alkaloid-Fällungsmitteln. wie z. B. Phosphorwolframsäure. Phosphormolybdänsäure. Tannin, Pikrinsäure. Jodjodkaliumlösung usw.. fällt, die Niederschläge nach dem Auswaschen in geeigneter Weise vom Fällungsmittel befreit und die Losung der wirksamen Hypophysensubstanz zur Kristallisation eindampft.
EMI1.1
Brei verrührt und mit Barythydrat bis zur alkalischen Reaktion versetzt. Hierauf wird vom phosphorwolframsauren Baryt abfiltriert und das Filtrat, das die freie wirksamt' Substanz und etwas Baryt enthält, mit Schwefelsäure neutralisiert.
Es wird vom Banum- sulfat abfiltriert und das Filtrat zur Kristallisation eingedampft. Das schwefelsaure Salz der wirksamen Substanz re. ultiert alsdann H1 gut ausgebildeten. schwach gelblich gefärbten
EMI1.2
Lösung im Vakuum bis zur Kristallisation eine basische Substanz, die sich leicht mit alkalischer Reaktion in Wasser löst und schwer löslich ist in Alkohol. Äther, Essigäther.
Axeton usw.
EMI1.3
**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.
<Desc / Clms Page number 1>
Process for obtaining the therapeutically effective substances contained in the pituitary gland
Substance in crystalline form.
It is known that extracts from the active part of the pituitary gland (hypophysis cerebri), the so-called infundibular part, have the ability to cause changes in blood pressure by contraction of the peripheral vascular muscles and to stimulate the uterus to contract by increasing the excitability of the uterine sympathetic nerves. Especially because of the latter property, which greatly intensifies labor pains. these pituitary extracts have achieved great therapeutic importance.
So far only diluted extracts from the lufundibular part of the pituitary gland have been marketed under the name Pituitrin, Pitglandol, etc. which are set in such a way that 1 cm3 of such a solution corresponds to 0 # 2 g infu7ndibular portion. However, since the content of active substance in the pituitary gland is not always the same and a simple determination of the value of the hypoplivus extracts is not known, the effect of these extracts naturally fluctuates within wide limits, which was noticeable in the therapeutic use of these preparations.
It has now succeeded. to isolate the active substance of the pituitary gland in the form of a salt which is crystallized and readily soluble in water. Since this salt is chemically pure, solutions can always be produced with the same effectiveness.
The procedure consists in that the extracts from the active part of the pituitary gland, completely freed from the protein, are mixed with the used alkaloid precipitants. such as B. phosphotungstic acid. Phosphomolybdic acid. Tannin, picric acid. Iodine iodine solution etc. falls, the precipitates are freed from the precipitant in a suitable manner after washing out and the solution of the active pituitary substance is evaporated for crystallization.
EMI1.1
Mix the pulp and add barythydrate to an alkaline reaction. Then the phosphotungstic acid barite is filtered off and the filtrate, which contains the free active substance and some barite, is neutralized with sulfuric acid.
The barium sulfate is filtered off and the filtrate is evaporated to crystallize. The sulfuric acid salt of the active substance re. Then H1 ends up well-trained. slightly yellowish in color
EMI1.2
Solution in vacuo until crystallization is a basic substance that easily dissolves in water with an alkaline reaction and is sparingly soluble in alcohol. Ether, vinegar ether.
Axeton etc.
EMI1.3
** WARNING ** End of DESC field may overlap beginning of CLMS **.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT64748T | 1912-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT64748B true AT64748B (en) | 1914-05-11 |
Family
ID=3586693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT64748D AT64748B (en) | 1912-10-04 | 1912-10-04 | Process for obtaining the therapeutically active substance contained in the pituitary in crystallized form. |
Country Status (1)
| Country | Link |
|---|---|
| AT (1) | AT64748B (en) |
-
1912
- 1912-10-04 AT AT64748D patent/AT64748B/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT64748B (en) | Process for obtaining the therapeutically active substance contained in the pituitary in crystallized form. | |
| DE1568280A1 (en) | Process for the preparation of magnesium or calcium salts of fumaric acid, optionally in the form of double salts with phosphoric acid and / or water-soluble aliphatic carboxylic acids | |
| DE1168441B (en) | Process for the production of a polyaminopolyacetic acid and its complex metal compounds | |
| AT112734B (en) | Process for the preparation of monocamphorates of the Solanaceae alkaloids. | |
| DE268841C (en) | ||
| DE659193C (en) | Process for the preparation of aminonitriles | |
| DE519053C (en) | Process for the preparation of salts of camphoric acid with scopolamine, hyoscyamine and atropine | |
| AT72460B (en) | Process for the production of concentrated acetic acid from dilute, aqueous solutions. | |
| DE458837C (en) | Process for the preparation of an aqueous solution of hexamethylenetetramine silver nitrate suitable for injections | |
| AT151971B (en) | Process for the preparation of n-hexylresorcinol sulfonic acid and its salts. | |
| DE579147C (en) | Process for the production of easily soluble salts of bile acids | |
| DE576445C (en) | Process for the production of primula acid (primula saponin) from primula species | |
| AT165307B (en) | Process for the preparation of a new benzilic acid derivative | |
| AT159318B (en) | Process for the preparation of readily water-soluble compounds of dialkylaminoalkyldiarylcarbinols. | |
| DE353932C (en) | Process for the preparation of thionaphthene sulfonic acid | |
| AT124884B (en) | Process for the production of hormone preparations. | |
| AT56874B (en) | Process for the preparation of esters of the hydroquina alkaloids | |
| DE344708C (en) | ||
| DE708768C (en) | Process for the preparation of acidic esters of the alkylated 1,4-naphthohydroquinones | |
| DE944953C (en) | Process for the preparation of a therapeutic agent consisting of the calcium salt of Ca-ethylene diamine tetraacetic acid | |
| AT60909B (en) | Process for the production of fermentable sugar or alcohol from concentrated cellulose solution. | |
| DE500915C (en) | Process for the preparation of 3,5-diiodo-N-methyl-2-oxopyridine | |
| DE594173C (en) | Process for the preparation of a remedy for rheumatism, gout, sciatica and the like like | |
| AT151299B (en) | Process for the production of pigskin green-like compounds. | |
| AT147483B (en) | Process for the preparation of compounds of methyl N-methyltetrahydronicotinate. |